News Sentiment

OACC sentiment intelligence

Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 32 relevant articles
Exchange NASDAQ United States
Sector Financial Services Market context
Industry Shell Companies Read-through group
Latest close 10.70 Week of 17 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Deals and strategy

92/100 classification confidence.

Company focus 31

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+0.1% over one week, +0.5% over four weeks, trend active, and near fair-value range.

Latest direct headline Negative

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Sees Large Decline in Short Interest

Market Reaction

Balanced read

55/100 confidence

News tone and price action are not far from neutral.

Primary event Deals and strategy 92/100 classification
One-week reaction 0.1% Price digesting
Trend fit Trend active 0.5% over four weeks
Fair value 2.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 18
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 31
Industry context 0
Sector context 1

Sources

Coverage mix

Publishers
MarketBeat 11
Stock Titan 3
dars.gov.et 2
TradingView 2
Investing.com 2
simplywall.st 1
Newsline 1
Bez Kabli 1

Event Lens

What the news is about

Classified themes
Deals and strategy 29
Earnings 1
Macro sensitivity 1
Market update 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 32
MarketBeat Direct company coverage

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Sees Large Decline in Short Interest

Short interest in Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) declined significantly in June, dropping 57.9% to 12,043 shares. The company, a SPAC sponsored by Oaktree Capital Management focusing on the life sciences sector, currently has a "Sell" consensus rating

Tone
Negative 39/100
Event
Deals and strategy
Published
15 Jul 2026 08:41
Source
MarketBeat
MarketBeat Direct company coverage

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Trading 0.2% Higher - What's Next?

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) saw its shares increase by 0.2% on Friday, trading at $10.7140 with very light volume. Despite this slight increase, the sentiment for the stock remains weak, with Weiss Ratings reaffirming a "sell (d)" rating and MarketB

Tone
Negative 34/100
Event
Deals and strategy
Published
11 Jul 2026 13:11
Source
MarketBeat
Newsline Direct company coverage

Oaktree Acquisition Corp. III Life Sciences Unit (OACCU) Holds Steady at $10.73 Amid Limited Trading Activity - Debt Free Companies

Oaktree Acquisition Corp. III Life Sciences Unit (OACCU) is trading steadily at $10.73, showing minimal volatility due to its status as a pre-merger SPAC unit awaiting a business combination announcement. The unit's price remains range-bound between support at $10.19 and resistan

Tone
Neutral 50/100
Event
Deals and strategy
Published
10 Jun 2026 09:40
Source
Newsline
Bez Kabli Direct company coverage

Oaktree SPAC draws trader attention after 5% filing

Oaktree Acquisition Corp. III Life Sciences (OACC), a SPAC, has garnered increased trader attention following a 5% ownership filing by Fort Baker Capital Management LP, which now owns 5.1% of its Class A shares. Goldman Sachs also reported shared voting power over 6.2% of shares.

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 May 2026 05:25
Source
Bez Kabli
Stock Titan Direct company coverage

Fort Baker Capital (OACC) reports 5.1% ownership of Oaktree III

Fort Baker Capital Management LP has reported a 5.1% beneficial ownership in Oaktree Acquisition Corp. III Life Sciences (OACC) through a Schedule 13G filing. The investment group jointly holds 1,000,000 Class A ordinary shares, indicating shared voting and dispositive power, but

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 May 2026 18:40
Source
Stock Titan
Stock Titan Direct company coverage

Oaktree Acquisition III Life Sciences (OACC) posts Q1 2026 interest income and flags going concern risk

Oaktree Acquisition Corp. III Life Sciences (OACC) reported a net income of $1,394,121 for Q1 2026, primarily from interest earned on its trust account. Despite this, management expressed substantial doubt about the company's ability to continue as a going concern, citing ongoing

Tone
Neutral 50/100
Event
Deals and strategy
Published
13 May 2026 21:09
Source
Stock Titan
MarketBeat Direct company coverage

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Short Interest Down 45.5% in April

Short interest in Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) significantly decreased by 45.5% in April, totaling 27,093 shares as of April 15th. This represents 0.1% of the company's shares and a short-interest ratio of 0.9 days. Analysts maintain a "Sell" rating f

Tone
Negative 36/100
Event
Deals and strategy
Published
27 Apr 2026 22:10
Source
MarketBeat
MarketBeat Direct company coverage

JPMorgan Chase & Co. Cuts Holdings in Oaktree Acquisition Corp. III Life Sciences $OACC

JPMorgan Chase & Co. significantly reduced its stake in Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) by 62.5% in the third quarter, selling 124,959 shares and retaining 74,817 shares valued at $783,000. While JPMorgan Chase decreased its holdings, other institutional

Tone
Negative 38/100
Event
Deals and strategy
Published
12 Apr 2026 09:10
Source
MarketBeat
MarketBeat Direct company coverage

Berkley W R Corp Buys 124,315 Shares of Oaktree Acquisition Corp. III Life Sciences $OACC

Berkley W R Corp significantly increased its stake in Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) by 125.2%, purchasing an additional 124,315 shares to own a total of 223,645 shares valued at $2.35 million. Other institutional investors like UBS Group AG also booste

Tone
Positive 67/100
Event
Deals and strategy
Published
15 Mar 2026 09:10
Source
MarketBeat
MarketBeat Direct company coverage

Radcliffe Capital Management L.P. Has $2.37 Million Holdings in Oaktree Acquisition Corp. III Life Sciences $OACC

Radcliffe Capital Management L.P. significantly increased its stake in Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) by 175.5% in the third quarter, now holding 225,662 shares valued at approximately $2.37 million. Other major investors like Goldman Sachs, Moore Capit

Tone
Positive 65/100
Event
Deals and strategy
Published
14 Mar 2026 10:52
Source
MarketBeat
Meyka Direct company coverage

Oaktree Acquisition Corp. III Life Sciences (OACCW) Competitors

This article provides a detailed comparison of Oaktree Acquisition Corp. III Life Sciences (OACCW) with numerous competitors within the Financial Services sector, specifically focusing on Shell Companies. It lists several peer companies along with key financial metrics such as ma

Tone
Neutral 50/100
Event
Deals and strategy
Published
12 Mar 2026 08:39
Source
Meyka
TradingView Direct company coverage

OACC Stock Price and Chart — NASDAQ:OACC

This article provides comprehensive financial data, charts, and technical analysis for Oaktree Acquisition Corp. III Life Sciences (OACC) stock on NASDAQ. It details key statistics, company information, performance metrics, and frequently asked questions regarding its stock price

Tone
Positive 61/100
Event
Deals and strategy
Published
04 Mar 2026 02:52
Source
TradingView
MarketBeat Direct company coverage

Short Interest in Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Grows By 24.4%

Short interest in Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) rose by 24.4% to 50,180 shares as of February 13th, representing 0.2% of the stock's shares and a short-interest ratio of 3.2 days. Several institutional investors, including Empyrean Capital Partners and

Tone
Neutral 50/100
Event
Deals and strategy
Published
03 Mar 2026 15:52
Source
MarketBeat
MarketBeat Direct company coverage

Short Interest in Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Declines By 21.5%

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) experienced a 21.5% decline in short interest during January, falling to 40,324 shares by January 30th. Institutional investors increased their exposure to OACC, with firms like Millennium Management, Goldman Sachs, Albert

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 Feb 2026 19:27
Source
MarketBeat
MarketBeat Direct company coverage

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Trading Up 0.4% - What's Next?

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) saw its stock rise by 0.4% during Friday's trading, with a significant increase in trading volume. Despite this uptick, the stock currently holds a consensus "Sell" rating from analysts, including a reiteration of "Sell (d

Tone
Negative 39/100
Event
Deals and strategy
Published
31 Jan 2026 08:00
Source
MarketBeat
TradingView Direct company coverage

Oaktree Acquisition Corp. III Life Sciences SEC 10-Q Report

Oaktree Acquisition Corp. III Life Sciences (OACC), a blank check company, filed its Form 10-Q report for the quarter ended September 30, 2025. The report details a net income of $1.97 million for the quarter and $5.50 million for the nine months, primarily from interest earned o

Tone
Neutral 50/100
Event
Deals and strategy
Published
13 Nov 2025 08:40
Source
TradingView
The Globe and Mail Direct company coverage

Oaktree Acquisition Corp. III Appoints New CFO

Oaktree Acquisition Corp. III Life Sciences Class A (OACC) has appointed George A. Martinez as its new Chief Financial Officer, succeeding Thomas Sweeney who resigned on October 29, 2025. Martinez, a Senior Vice President at Oaktree Capital Management and a Certified Public Accou

Tone
Neutral 50/100
Event
Deals and strategy
Published
30 Oct 2025 10:10
Source
The Globe and Mail
Investing.com Australia Direct company coverage

Oaktree Acquisition Corp. III Life Sciences appoints David A. Berry as director By Investing.com - Investing.com Australia

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) announced the appointment of David A. Berry, MD, PhD, as an independent director. Dr. Berry, co-founder of Averin Capital and former partner at Flagship Pioneering, brings extensive experience from the life sciences sector

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Oct 2025 12:04
Source
Investing.com Australia
Investing.com South Africa Direct company coverage

Oaktree Acquisition Corp. III Life Sciences appoints David A. Berry as director By Investing.com - Investing.com South Africa

This article reports on the appointment of David A. Berry as a director for Oaktree Acquisition Corp. III Life Sciences. The article content itself is unfortunately missing due to an application error on the source website.

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Oct 2025 00:16
Source
Investing.com South Africa
Investing.com Direct company coverage

Oaktree Acquisition Corp. III Life Sciences appoints David A. Berry as director - Investing.com

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) has appointed David A. Berry, MD, PhD, as an independent director, who will also serve on the audit, nominating, and compensation committees. Dr. Berry brings extensive experience from Averin Capital and Flagship Pioneerin

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Oct 2025 21:34
Source
Investing.com
Investing.com Direct company coverage

Oaktree Acquisition Corp. III Life Sciences appoints David A. Berry as director

Oaktree Acquisition Corp. III Life Sciences has appointed Dr. David A. Berry as an independent director, who will also serve on the audit, nominating, and compensation committees. Dr. Berry brings extensive experience from Averin Capital and Flagship Pioneering, along with his me

Tone
Positive 70/100
Event
Deals and strategy
Published
17 Oct 2025 17:34
Source
Investing.com
Stock Titan Direct company coverage

Oaktree Acquisition III (OACC) Stock Price, News & Analysis

Oaktree Acquisition Corp. III Life Sciences (OACC) is a blank check company operating in the Financial Services sector, with its securities listed on Nasdaq. The article details its business structure, including units, Class A ordinary shares, and redeemable warrants, and highlig

Tone
Neutral 50/100
Event
Deals and strategy
Published
26 Apr 2025 05:09
Source
Stock Titan
MarketBeat Direct company coverage

Oaktree Acquisition Corp. III Life Sciences (OACC) Stock Price, News & Analysis

Oaktree Acquisition Corp. III Life Sciences (OACC) is a SPAC focused on business combinations within the life sciences sector, sponsored by Oaktree Capital Management. As of February 14, 2025, OACC shares are trading at $10.70, up 1.1% since January 1st, 2026. The company is acti

Tone
Positive 65/100
Event
Deals and strategy
Published
14 Feb 2025 02:52
Source
MarketBeat
Oaktree Capital Management Direct company coverage

The Roundup: Top Takeaways from Oaktree’s Quarterly Letters - December 2023 Edition

Oaktree Capital Management's December 2023 "Roundup" synthesizes insights from its experts on the 2023 credit markets and future opportunities. Key takeaways include Howard Marks's perspective on interest rates and inflation, suggesting a "new normal" for investment strategies. O

Tone
Positive 71/100
Event
Macro sensitivity
Published
14 Dec 2023 13:09
Source
Oaktree Capital Management